Recent Updates in The Role of Immunotherapies in Early NSCLC: Translating Evidence to Clinical Practice

A panel of experts who treat patients with non-small cell lung cancer provides an overview of staging, molecular testing and treatment options in stage I-IIIB non-small cell lung cancer.

Ben Levy, MD offers insight into how he approaches the selection of the optimal treatment strategy in early-stage non-small cell lung cancer.

Overview and clinical implications of the CheckMate-816 study of neoadjuvant nivolumab plus platinum chemotherapy versus chemotherapy alone in early-stage NSCLC.

David Harpole, MD, discusses study design, results and clinical implications of the AEGEAN study of perioperative immunotherapy (neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in the treatment of early-stage NSCLC

Sandip Patel, MD, reviews the study design, results and clinical implications of the KEYNOTE-671 and NEOTORCH studies that evaluated perioperative chemoimmunotherapy in the treatment of early-stage NSCLC.

Expert perspectives on selecting between neoadjuvant and perioperative chemoimmunotherapy in patients with resectable early-stage NSCLC.

A panel of experts offers their insights into which patients with resectable early-stage NSCLC might be suitable for neoadjuvant versus adjuvant chemoimmunotherapy.

Sandip Patel, MD, and Ben Levy, MD, discuss the results and clinical implications of the IMPower-010 and KEYNOTE-091 studies of adjuvant immunotherapy in NSCLC.

Expert panelists discuss the characterization of patients with unresectable, early-stage NSCLC and what their standard treatment approach is for this patient population.

Ben Levy, MD, reviews the 5-year update and clinical implications of the PACIFIC study which evaluated consolidation immunotherapy in unresectable early-stage NSCLC.

Sandip Patel, MD, shares his expert perspectives on novel combination consolidation immunotherapy regimens that are under evaluation in unresectable early-stage NSCLC.

Tina Cascone, MD, Ben Levy, MD, and Sandip Patel, MD, offer insights into the treatment approach in patients with unresectable early-stage NSCLC who are unsuitable for consolidation durvalumab or who progress on consolidation durvalumab.

A panel of experts share unmet needs and clinical practice pearls for community oncologists regarding the treatment of patients with early-stage NSCLC.